PGR and breast cancer: Though our study has limited ability to make broad conclusions with respect to appropriate treatment options for patients with borderline ER+ expression and existence of the ER−/PR+ breast cancer subtype, it emphasises the need for retesting patients classified with ER−/PR+ breast cancer and suggests the clinical rarity of this pathological subtype.